Table 1.

Clinical and laboratory features.

CDC, n = 4	Pt 1	Pt 2	Pt 3	Pt 4
Clinical and laboratory features
Age at diagnosis, yo	73	61	78	53
Sex	male	female	female	male
Radical nefrectomy	yes	no	yes	yes
Metastases at diagnosis	no	yes	yes	no
Metastatic sites pre-cabozantinib
lung		X
brain
lymph nodes				X
liver
bone		X	X
renal loggia	X	X
Best response to cabozantinib	stable disease	progression of disease	partial response	stable disease
Metastatic sites pre-nivolumab
lung	X	X
brain
lymph nodes	X			X
liver	X
bone	X	X	X
renal loggia	X	X
Best response to nivolumab	progression of disease	stable disease	partial response	stable disease
Clinical benefit with nivolumab	yes	yes	yes	yes
IMDC score
pre-cabozantinib	intermediate	intermediate	intermediate	intermediate
pre-nivolumab	intermediate	intermediate	intermediate	intermediate
NLR
pre-nivolumab	3.8	2.2	2.9	3.0

CDC, collecting duct carcinoma; IMDC, International Metastatic RCC Database Consortium risk score; NLR, neutrophil-lymphocyte ratio; Pt, patient; yo, years old.